NZ's PHARMAC awards sole supply to Eprex to Janssen-Cilag

5 August 2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has awarded sole subsidised supply status in the community, and hospital supply status in District Health Boards (DHB) hospitals, to US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag’s brand of erythropoietin, Eprex (erythropoietin alfa).

In summary, the effect of the decision is that:

Eprex will be the only funded brand of erythropoietin in the community and the only brand able to be used in DHB hospitals, subject to a 5% discretionary variance (DV) limit, from March 1, 2015 to February 28, 2018; and
Access to erythropoietin will be widened to include:

patients with myelodysplasia; and
patients for whom blood transfusion is not a viable treatment option (hospital only).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK